TGTX TG Therapeutics, Inc. Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
14:28
Sep 22
Mark Minervini
Minervini holds TGTX among resilient longs
Maintain long TGTX, disclosed among a small basket of resilient longs that held stops and performed well through the stealth market correction.
TGTX TG Therapeutics, Inc. Long 1ST — —
16:29
Aug 10
psyduckcapital
Starter in TGTX, rotating into biotech
Opens a starter position in $TGTX as part of adding more de-risked biotech, because the AI trade looks lacklustre outside select hyperscalers.
TGTX TG Therapeutics, Inc. Long 1ST Position: Opened —
18:11
Aug 07
psyduckcapital
Great product, poor risk/reward at $7.5B
BRIUMVI is a great product with strong traction, but at a $7.5 billion market cap the risk/reward on $TGTX is still not great; the post-earnings rebound from $46 to $50 may simply be short covering.
TGTX TG Therapeutics, Inc. Avoid — —
Log in to see ideas

About TGTX Investor Commentary

Across the available history and selected sources, Buzzberg tracks TGTX (TG Therapeutics, Inc.) across 6 sources: 3 bullish vs 0 bearish calls from 6 authors. Historical directional balance: 17% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 18 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: Mark Minervini, psyduckcapital.